Intratio
Quantitative Research
Skip to main content
AI Market Summary
Loading market intelligence...
  • Sign in
    My account
    Logout
AI 90-DAY FORECAST
NEUTRAL SIGNAL
██.█% Sign up free to reveal

Denali Therapeutics Inc. (DNLI) AI Forecast

Our AI analyzed Denali Therapeutics Inc.. Create a free account and follow it to see the 90-day price prediction.

✓ Free account • ✓ 30-day free trial

$DNLI Neutral Signal Full forecast available
Sign Up Free

Denali Therapeutics Inc. (DNLI) Stock Forecast 2025

Denali Therapeutics Inc. (DNLI) AI Stock Price Forecast & Investment Analysis

Denali Therapeutics Inc. Stock Price Chart and Technical Analysis

Loading chart...

Denali Therapeutics Inc. (DNLI) - Comprehensive Stock Analysis & Investment Research

Deep dive into Denali Therapeutics Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Analysis updated on July 27, 2026, 3:42 p.m. (UTC)

Denali Therapeutics Inc. Investment Summary

When evaluating whether Denali Therapeutics Inc. (DNLI) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.

Company Profile

Denali Therapeutics Inc. (DNLI) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. . With a market capitalization of $4 billion, the company is a mid-cap stock that typically offers a balance between growth potential and established business operations.

Financial Performance Analysis

Our comprehensive financial analysis covers Denali Therapeutics Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...

AI Price Predictions

Get AI-powered 7-day, 30-day and 90-day price forecasts for Denali Therapeutics Inc. along with confidence scores and detailed analysis...

Investment Considerations

Expert analysis of whether Denali Therapeutics Inc. is suitable for your investment objectives, risk tolerance, and time horizon...

Continue Reading Full Analysis

Get the complete investment breakdown for Denali Therapeutics Inc.

Sign Up Free
Corporate Identity

Denali Therapeutics Inc. (Stock Symbol: DNLI) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.

Leadership & Workforce

Detailed information about Denali Therapeutics Inc.'s leadership team, workforce size, and organizational structure...

Market Classification

Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Denali Therapeutics Inc....

Sector & Industry Analysis

In-depth sector dynamics and industry context for Denali Therapeutics Inc....

Unlock Full Company Profile

Get complete details about Denali Therapeutics Inc.

Sign Up Free
Revenue & Growth Analysis
Profitability Metrics

Net profit margin, gross margin, and operating margin analysis for Denali Therapeutics Inc....

Market Valuation

P/E ratio, price-to-book, and valuation multiples for Denali Therapeutics Inc....

Return Metrics

Return on equity (ROE), return on assets (ROA), and capital efficiency for Denali Therapeutics Inc....

Unlock Financial Analysis

Get complete financial metrics for Denali Therapeutics Inc.

Sign Up Free
AI ANALYSIS AVAILABLE

Unlock Denali Therapeutics Inc.'s AI Price Forecast

Join 10,000+ investors using our 67%+ accurate AI predictions

4,000+ Stocks Analyzed
67%+ Accuracy Rate
Daily Updates
Start 30-Day Free Trial →

✓ 30-day free trial • ✓ Cancel anytime

Strategic Market Position

Denali Therapeutics Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a mid-cap company, it occupies an attractive position balancing growth potential with established operations. Mid-caps often represent the 'sweet spot' for investors seeking companies that have proven their business models but still have meaningful runway for expansion. These companies are large enough to have competitive advantages but nimble enough to adapt quickly to market changes.

Industry Competitive Landscape

Denali Therapeutics Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.

Operational Efficiency

The company currently shows negative free cash flow of $-419 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.

Financial Strength & Leverage

Current ratio of 9.28 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.

Denali Therapeutics Inc. (DNLI) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Denali Therapeutics Inc. stock analysis.

Deep dive into Denali Therapeutics Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Denali Therapeutics Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Denali Therapeutics Inc.:

P/B Ratio 4.01x
Market Cap $3.72B
Book Value/Share $5.84
FCF/Share $-2.64
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Denali Therapeutics Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Denali Therapeutics Inc.: An ROE of -10.2% indicates room for improvement in shareholder value creation.

ROE -10.2%
ROA -7.5%
ROIC -8.9%
Operating Margin -4016.9%
Net Margin -3693.9%
EBT Margin -4016.9%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Denali Therapeutics Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Denali Therapeutics Inc.: A current ratio of 9.28 indicates strong liquidity.

Current Ratio 9.28x
D/E Ratio 0.37x
Financial Leverage 1.37x
Working Capital $913M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Denali Therapeutics Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Denali Therapeutics Inc.: Free cash flow of $-419M indicates cash challenges that need attention.

Operating Cash Flow $134M
Free Cash Flow -$419M
Capital Spending -$554M
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Denali Therapeutics Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Denali Therapeutics Inc.:

Understanding Financial Statement Data

What these metrics mean: Key figures from Denali Therapeutics Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Denali Therapeutics Inc.:

Income Statement
Operating Income -$102M
Net Income -$94M
R&D Expense $83M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 1023%
Cash & Short-term Investments 388%
Total Liabilities 340%
Short-term Debt 70%
Dividend & Shareholder Information
Shares Outstanding 159M
Growth Metrics (YoY)
Net Income Growth -3693.9%

Latest Denali Therapeutics Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Denali Therapeutics Inc. (DNLI) stock price and investment outlook.

📰 Loading...

Denali Therapeutics Inc. Competitors & Peer Analysis - Life Sciences Sector

Comparative analysis of Denali Therapeutics Inc. against industry peers and competitors in the Life Sciences sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio
ABOS ██% $157M x 1.8x
ABPO ██% $1M x x
ACOG ██% $179M x 3.1x
ADAPY ██% $8M x x
ADMA ██% $1.94B 11.8x 5.0x
ADPT ██% $3.56B x 16.5x
AGEN ██% $238M 3.7x x
AGTX ██% $800K x x
AIM ██% $7M x 3.3x
ALEC ██% $165M x 15.9x
ALGS ██% $29M x 0.9x
ALLO ██% $628M x 2.3x
ALVO ██% $992M x x
AMGN ██% $200.50B 25.7x 21.8x
APGE ██% $10.05B x x
APTOF ██% $4M x x
ARGX ██% $57.22B x x
ARMP ██% $192M x x
ARTV ██% $492M x 5.6x
ATRA ██% $70M x x
ATYR ██% $49M x 0.8x
AURA ██% $745M x 6.9x
AUTL ██% $405M x 3.7x
AVXL ██% $230M x 1.8x
BCAB ██% $6M x x
BCDA ██% $14M x x
BCLI ██% $11M x x
BCRX ██% $2.38B x x
BDTX ██% $105M x 1.0x
BEAM ██% $2.66B x 2.3x
BIIB ██% $29.53B 21.5x 1.6x
BNTX ██% $23.28B x x
CABA ██% $444M x 4.3x
CADL ██% $722M x 5.2x
CCCC ██% $380M x 1.6x
CELZ ██% $5M x 0.9x
CERO ██% $500K x x
CGEM ██% $1.06B x 2.9x
CGEN ██% $221M 3.1x 2.2x
CGON ██% $6.26B x 5.7x
CGTX ██% $86M x 2.9x
CHRS ██% $221M 1.2x 2.8x
CLDI ██% $2M x 0.4x
CLLS ██% $279M x x
CMPX ██% $382M x 2.1x
CPMV ██% $5M x x
CRDF ██% $65M x 1.9x
CRDL ██% $123M x x
CRIS ██% $9M x 0.7x
CRSP ██% $4.58B x 2.5x
CSBR ██% $83M x 19.5x
CVM ██% $21M x 3.0x
DBVT ██% $820M x 5.1x
DNA ██% $489M x 1.1x
DNLI ██% $3.72B x 4.0x
DTIL ██% $189M x 2.5x
DYAI ██% $44M x x
EDIT ██% $419M x 95.0x
ELUT ██% $40M 0.8x 1.8x
ENGN ██% $127M x 0.5x
ENTX ██% $99M x 9.3x
ENZN ██% $59M x 0.3x
ESLA ██% $32M x x
EVAX ██% $25M x x
EXEL ██% $14.12B 16.9x 7.3x
EXOZ ██% $40M x 26.1x
FATE ██% $293M x 1.6x
FDMT ██% $543M x 1.2x
FENC ██% $351M x 9.3x
GILD ██% $162.53B 17.6x 6.9x
GLUE ██% $1.94B x 3.7x
GNTA ██% $80M x 6.4x
GPLB ██% $260K x x
GRML ██% $30M x 0.6x
HALO ██% $9.58B 27.5x 43.6x
HUMA ██% $172M x 14.8x
IBRX ██% $7.75B x x
IKT ██% $366M x 2.2x
IMA ██% $63M x 0.5x
IMCR ██% $1.81B x 4.6x
IMTX ██% $1.25B x x
IMVT ██% $8.03B x 9.4x
INAB ██% $12M x 0.5x
INKT ██% $50M x x
INMB ██% $46M x 2.3x
INTS ██% $11M x 1.1x
IOVA ██% $2.25B x 3.1x
IPSC ██% $391M x 1.5x
IVVD ██% $172M x 0.9x
JATT ██% $88M x 0.4x
JSPR ██% $24M x 7.1x
KLRS ██% $90M x 1.3x
KOD ██% $2.55B x 22.7x
KRYS ██% $9.64B 42.8x 7.6x
KYMR ██% $9.07B x 5.9x
KYTX ██% $441M x 2.3x
LCTX ██% $267M x 5.0x
LENZ ██% $158M x 0.6x
LIFE ██% $1.87B x 32.2x
LIMN ██% $7M x x
LONA ██% $68M x 1.4x
LXEO ██% $349M x 1.5x
MAZE ██% $1.53B x 4.5x
MESO ██% $2.09B x x
MGTX ██% $986M x x
MGX ██% $46M x 0.3x
MOLN ██% $160M x x
MRNA ██% $22.64B x 3.1x
NBIX ██% $17.52B 26.2x 5.1x
NMRA ██% $281M x 4.0x
NVAX ██% $1.29B x x
OCGN ██% $430M x 74.0x
OTLK ██% $247M x x
PALI ██% $338M x 2.7x
PASG ██% $16M x 1.3x
PCVX ██% $8.03B x 2.7x
PHGE ██% $2M x x
PLUR ██% $19M x x
PLX ██% $189M 12.3x 2.8x
PMCB ██% $6M x 0.2x
PRME ██% $536M x 7.0x
PROK ██% $459M x x
PTHS ██% $96M x 2.7x
QGEN ██% $8.99B x 2.4x
QNCX ██% $18M 2.1x 1.1x
REPL ██% $865M x 5.2x
RGEN ██% $7.76B 151.0x 3.7x
RGNX ██% $656M x 31.1x
RLAY ██% $4.14B x 6.5x
RVMD ██% $37.78B x 25.2x
RXRX ██% $1.60B x 1.6x
SABS ██% $274M x 1.2x
SANA ██% $866M x 7.3x
SCLX ██% $52M x x
SCNI ██% $1M x 0.2x
SGMO ██% $29M x x
SGMOQ ██% $25M x x
SLDB ██% $804M x 2.2x
SLXN ██% $3M x 8.7x
SNTI ██% $13M x 5.2x
SRRK ██% $5.89B x 21.4x
SRZN ██% $231M x x
STRO ██% $391M x x
TARA ██% $226M x 1.3x
TARS ██% $2.52B x 7.2x
TCRX ██% $52M x 0.5x
TECH ██% $11.23B 102.5x 5.4x
TECX ██% $594M x 2.6x
TIL ██% $48M x 0.4x
TNYA ██% $168M x 1.6x
TSHA ██% $1.67B x 7.9x
TVGN ██% $20M x x
TWST ██% $5.75B x 12.6x
VACH ██% $541M 80.4x x
VALN ██% $516M x x
VCEL ██% $2.30B 107.1x 6.5x
VIR ██% $1.51B x 1.9x
VIVS ██% $2M x 0.4x
VOR ██% $1.03B x x
VXRT ██% $121M 3.3x 1.3x
VYGR ██% $185M x 1.1x
WINT ██% $340K x x
XFOR ██% $376M x 2.2x
ZEOX ██% $14M x 19.4x
ZIVO ██% $19M x x
ZURA ██% $502M x 2.3x
Reveal all forecasts See exact % predictions for all competitors
Sign up free

Frequently Asked Questions - Denali Therapeutics Inc. Stock Forecast

How accurate are Denali Therapeutics Inc. stock predictions?

Our AI model shows a -15% Spearman correlation coefficient for DNLI predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Denali Therapeutics Inc. stock price forecasts?

Our analysis considers Denali Therapeutics Inc.'s financial metrics, Life Sciences sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Denali Therapeutics Inc. a good investment in 2025?

Based on our AI analysis, Denali Therapeutics Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Denali Therapeutics Inc. forecasts updated?

Denali Therapeutics Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want a simpler view of Denali Therapeutics Inc.?

View simplified analysis on AI Stock Finder →

My Portfolio

Investment Dashboard

Loading your portfolio...